Drug Type Antibody-photosensitizer conjugates |
Synonyms- |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lung Cancer | Phase 2 | - | 01 Jun 2025 | |
Nodule of lung | Phase 2 | - | 01 Jun 2025 | |
Invasive Mammary Carcinoma | Phase 2 | - | 01 Jun 2021 | |
Noninfiltrating Intraductal Carcinoma | Phase 2 | - | 01 Jun 2021 | |
Barrett Esophagus | Phase 2 | Netherlands | 29 Jul 2019 | |
Esophageal Carcinoma | Phase 2 | Netherlands | 29 Jul 2019 | |
Klatskin Tumor | Phase 2 | Netherlands | 01 Apr 2019 | |
Soft Tissue Sarcoma | Phase 2 | Netherlands | 01 May 2018 | |
Breast Cancer | Phase 2 | - | - | |
Pancreatic Cancer | Phase 2 | - | - |
NCT02743975 (Pubmed) Manual | Phase 1 | 10 | bevacizumab-800CW | mxuokrpdtz(ixaqsmxxgp) = 1.3, 1.5 and 2.5 for 4.5mg, 10mg and 25mg groups btopedgjxv (ifcvymphny ) | Negative | 09 Jun 2022 |